

Impavido approved to treat tropical parasitic disease

March 20 2014

(HealthDay)—Impavido (miltefosine) has been approved by the U.S. Food and Drug Administration to treat adults with leishmaniasis, a tropical disease caused by a parasite that's transmitted by the bites of sand flies.

Most Americans who contract the disease do so traveling overseas, the agency said in a news release.

The drug's safety and effectiveness were evaluated in clinical trials involving more than 700 people. Impavido's label will include a boxed warning that the medication could harm a developing fetus and shouldn't be taken by pregnant women.

Common side effects include nausea, vomiting, diarrhea, headache, loss of appetite, dizziness, [abdominal pain](#), itching, fatigue and elevated liver enzymes, the FDA said.

The drug is produced by Paladin Therapeutics, based in Montreal.

More information: The U.S. Centers for Disease Control and Prevention has more about [leishmaniasis](#)

Copyright © 2014 [HealthDay](#). All rights reserved.

Citation: Impavido approved to treat tropical parasitic disease (2014, March 20) retrieved 27

April 2024 from

<https://medicalxpress.com/news/2014-03-impavido-tropical-parasitic-disease.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.